ERC Consolidator Grant · 2020
Modulating the gut microbiome to enhance drug efficacy
Individual response rates to drugs that are widely prescribed to treat common diseases are typically in the range of 50-75%, yet the slow progress and high costs associated with new drug development do not meet the urgent need for new treatment options, particularly given the rapidly increasing burden of chronic diseases. This ERC project tackles this pressing issue by defining the impacts of the gut microbiome and genetics on drug metabolism, ultimately enabling personalized approaches that enhance efficacy and safety of already marketed drugs via microbiome modulation. I will start with 23 common drugs used to treat chronic cardiometabolic and psychiatric disorders that threaten public…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.